What peri‑operative considerations should an anesthesiologist have for a patient with systemic lupus erythematosus (SLE) undergoing surgery?

Perioperative Anesthetic Considerations for SLE Patients Undergoing TAHBSO

For patients with SLE undergoing total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAHBSO), anesthesiologists must focus on medication management based on disease severity, assess multi-organ involvement that affects anesthetic risk, and prepare for increased perioperative complications including infection, thrombosis, and cardiovascular events.

Medication Management Strategy

Disease Severity Classification is Critical

The primary determinant of perioperative medication management is whether the patient has severe versus non-severe SLE 1.

Severe SLE is defined as disease with risk of permanent organ damage (lupus nephritis, CNS lupus, severe hematologic involvement, or vasculitis) 1.

For Non-Severe SLE:

• Continue through surgery: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and apremilast at usual doses 1
• Withhold 1 week prior: mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, tacrolimus 1
• Withhold prior to surgery: belimumab and rituximab 1
• Rationale: Non-severe patients can tolerate temporary medication withdrawal and be monitored closely postoperatively for flares without risk of permanent organ damage 1

For Severe SLE:

• Continue through surgery: mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, tacrolimus, anifrolumab, and voclosporin at usual doses 1
• Continue belimumab through surgery 1
• For rituximab: Continue and plan surgery during last month of dosing cycle (months 5-6 if dosed every 6 months) 1
• Critical caveat: Consult rheumatology; patients stable >6 months or with recurrent severe infections may discontinue medications perioperatively 1

Glucocorticoid Management:

• Continue current daily dose rather than administering stress-dose steroids 1
• This represents a shift from historical practice of supraphysiologic dosing 1
• Patients on chronic steroids still require their baseline dose to prevent adrenal insufficiency 2

Medication Restart Protocol:

• Resume withheld medications ~14 days postoperatively once wound shows healing, sutures/staples removed, no significant swelling/erythema/drainage, and no ongoing infection 1

Multi-System Assessment Requirements

Cardiovascular Evaluation

• SLE patients have significantly elevated perioperative cardiovascular risk 3
• Women with SLE undergoing low-risk procedures have 1.54× mortality and 1.40× composite CVD event risk compared to non-SLE patients 3
• High-risk procedures carry 2.52× mortality risk 3
• Assess for accelerated atherosclerosis, valvular disease (Libman-Sacks endocarditis), pericarditis, and myocarditis 4
• Consider preoperative cardiology consultation for intermediate-to-high risk procedures 3

Hematologic Considerations

• Thrombocytopenia: Common in SLE; platelet count >50,000/mm³ generally acceptable for neuraxial anesthesia 2
• Antiphospholipid syndrome: Present in ~30% of SLE patients; assess for history of thrombosis or pregnancy morbidity 4
• Anemia: SLE patients have significantly higher rates of postoperative anemia and transfusion requirements 5
• Obtain complete coagulation profile including lupus anticoagulant, anticardiolipin antibodies 4

Renal Function

• Lupus nephritis affects medication clearance and fluid management 4
• Assess baseline creatinine, proteinuria, and glomerular filtration rate 4
• Adjust anesthetic drug dosing accordingly 4

Pulmonary Assessment

• Evaluate for interstitial lung disease, pulmonary hypertension, pleural effusions, and shrinking lung syndrome 4
• Patients may present with dyspnea on exertion requiring preoperative optimization 2

Airway Considerations

• Assess for temporomandibular joint involvement limiting mouth opening 4
• Cricoarytenoid arthritis may complicate intubation 4
• Cervical spine involvement in some patients 4

Infection Risk Management

• SLE patients have significantly elevated perioperative infection rates 5
• Periprosthetic infection risk is higher in SLE patients undergoing arthroplasty 5
• Strict asepsis mandatory for all invasive procedures including neuraxial techniques 2
• Consider prophylactic antibiotics per institutional protocols 5

Intraoperative Management

Temperature Control

• Maintain normothermia to minimize Raynaud's phenomenon impact 2
• Use forced-air warming devices 2

Regional Anesthesia Considerations

• Neuraxial techniques acceptable with platelet count >50,000/mm³ 2
• Weigh benefits against risks in patients with antiphospholipid syndrome 4
• Document thorough neurologic exam preoperatively given CNS lupus risk 4

Monitoring

• Standard ASA monitors plus consideration for arterial line in patients with significant cardiopulmonary involvement 4
• Vigilant fluid management given potential renal impairment 4

Postoperative Considerations

• Longer hospital stays expected: SLE patients have significantly prolonged hospitalizations compared to non-SLE patients 5
• Higher healthcare costs: Anticipate increased resource utilization 5
• Thromboprophylaxis: Critical given antiphospholipid syndrome prevalence and immobility 4
• Monitor for disease flare, particularly if immunosuppressants were withheld 1
• Early mobilization to reduce thromboembolic risk 5

Critical Pitfalls to Avoid

• Do not assume all SLE is the same: Severity classification fundamentally changes medication management 1
• Do not automatically give stress-dose steroids: Continue baseline dose only 1
• Do not overlook antiphospholipid syndrome: Separate entity requiring specific thromboprophylaxis 4
• Do not underestimate cardiovascular risk: Even "low-risk" procedures carry elevated mortality in SLE 3
• Do not restart immunosuppressants too early: Wait for adequate wound healing (~14 days) 1